AVXL
Anavex Life Sciences Corp.
Healthcare · Biotechnology · NMS
$2.57
Data: 2026-05-13
✗ ETHICAL FAIL

MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$282M
Total market value of the company
Trailing P/E
0.00
Forward P/E
-21.75
Based on estimated future earnings — lower means cheaper
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
ROE
-33.6%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$22.00
+756% from current price — median analyst estimate
Recommendation
NONE
Consensus view from 2 analysts covering this stock
About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

https://www.anavex.com

Country: United States Employees: 34 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% PASS
Debt must be below 33% of total assets
Cash Ratio
46.7% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKDOWN
Price trending down — defensive positioning
Sharpe Ratio
0.202
Positive but modest risk-adjusted returns
Kelly Fraction
-0.0025
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.231
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-18.5%
Historical annualised return based on price data
Max Drawdown
-80.2%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
22
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.25
Moves slightly more than the broader market
52W High
$13.99
82% below the year high
52W Low
$2.61
-2% above the year low
Avg Volume
1,343,338
Average daily shares traded — higher means easier to buy and sell
Short Ratio
18.4
Days it would take all short sellers to cover — higher means more crowded
Short % Float
21.4%
Very high short interest — potential squeeze candidate
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.46
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.00
Conservative use of debt — low financial risk
Current Ratio
20.87
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
20.81
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Free Cash Flow
$-21,833,624
Negative — the business is spending more than it generates
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
$-39,947,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
2
Target High
$24.00
Target Median
$22.00
Target Low
$20.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2025-09-11 MISSLING CHRISTOPHER U Chief Executive Officer 187,500 $945,000
2025-06-05 THOMAS STEFFEN PHD Director 50,000 $88,000
2025-03-24 MISSLING CHRISTOPHER U Chief Executive Officer 500,000 $460,000
2024-06-14 DONHAUSER PETER D.O. Director 2,835 $10,319
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.